| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EIF4A3 |
| Uniprot No | P38919 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-411aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMATTAT MATSGSARKR LLKEEDMTKV EFETSEEVDV TPTFDTMGLR EDLLRGIYAY GFEKPSAIQQ RAIKQIIKGR DVIAQSQSGT GKTATFSISV LQCLDIQVRE TQALILAPTR ELAVQIQKGL LALGDYMNVQ CHACIGGTNV GEDIRKLDYG QHVVAGTPGR VFDMIRRRSL RTRAIKMLVL DEADEMLNKG FKEQIYDVYR YLPPATQVVL ISATLPHEIL EMTNKFMTDP IRILVKRDEL TLEGIKQFFV AVEREEWKFD TLCDLYDTLT ITQAVIFCNT KRKVDWLTEK MREANFTVSS MHGDMPQKER ESIMKEFRSG ASRVLISTDV WARGLDVPQV SLIINYDLPN NRELYIHRIG RSGRYGRKGV AINFVKNDDI RILRDIEQYY STQIDEMPMN VADLI |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EIF4A3重组蛋白的3篇参考文献示例(注：文献信息为示例性质，非真实存在)：
1. **标题**：*Structural insights into EIF4A3 function in the exon junction complex*
**作者**：Zhang L, et al.
**摘要**：本研究通过重组表达纯化人源EIF4A3蛋白，结合X射线晶体学解析其与RNA结合的构象变化，揭示了EIF4A3在剪接后复合体(EJC)中依赖ATP水解调控mRNA定位及无义介导衰变的分子机制。
2. **标题**：*Recombinant EIF4A3 interacts with MAGOH/Y14 to regulate splicing fidelity*
**作者**：Müller-McNicoll M, et al.
**摘要**：利用重组EIF4A3与剪接因子MAGOH/Y14的体外结合实验，证明EIF4A3通过形成复合体增强剪接体对异常mRNA的识别能力，并揭示了其在维持基因表达质量控制中的关键作用。
3. **标题**：*EIF4A3 recombinant protein suppresses tumor growth by modulating oncogenic splicing*
**作者**：Wang X, et al.
**摘要**：通过体外重组EIF4A3蛋白的功能研究，发现其过表达可抑制癌细胞中异常剪接事件(如BCL2家族基因)，诱导凋亡，为靶向EIF4A3的抗癌治疗提供实验依据。
(注：以上内容为模拟示例，实际文献需通过学术数据库检索确认。)
**Background of EIF4A3 Recombinant Protein**
EIF4A3 (Eukaryotic Initiation Factor 4A-III) is a member of the DEAD-box RNA helicase family, playing critical roles in mRNA processing, quality control, and translation regulation. It is a core component of the Exon Junction Complex (EJC), a multiprotein assembly deposited on spliced mRNAs during pre-mRNA processing. The EJC marks exon-exon boundaries and influences downstream events such as mRNA export, localization, translation, and nonsense-mediated mRNA decay (NMD), a surveillance mechanism that degrades transcripts with premature termination codons.
EIF4A3’s helicase activity facilitates structural remodeling of RNA-protein complexes, enabling EJC assembly and function. Unlike its paralogs EIF4A1 and EIF4A2 (involved in translation initiation), EIF4A3 is specialized for mRNA quality control. It binds RNA in an ATP-dependent manner and collaborates with EJC core proteins (e.g., MAGOH, Y14) to stabilize mRNA interactions. Dysregulation of EIF4A3 is linked to diseases, including cancer and neurodevelopmental disorders, due to its role in maintaining transcriptome integrity.
Recombinant EIF4A3 proteins are engineered for in vitro studies to dissect its molecular mechanisms, including RNA binding, ATP hydrolysis, and interactions with EJC partners. These proteins are typically expressed in bacterial or eukaryotic systems, purified via affinity tags, and validated for enzymatic activity. Research using recombinant EIF4A3 has advanced understanding of NMD pathways, splicing-coupled mRNA surveillance, and potential therapeutic targeting in diseases caused by aberrant RNA metabolism. Its unique position at the nexus of mRNA processing and quality control makes it a focal point for RNA biology and biomedical research.
×
